Abstract 520P
Background
Adding atezolizumab to the established etoposide and carboplatin chemotherapy (AECb) for extensive-stage small cell lung cancer (ES-SCLC) is now standard, following success of Impower 133 trial. Controlling central nervous system (CNS) progression is pivotal for patients’ survival and quality of life. We explored a role of atezolizumab in controlling brain metastasis in ES-SCLC patients.
Methods
A total of 156 patients, diagnosed with ES-SCLC and received 1st line chemotherapy between August 2016 and July 2022 at Korea University Guro Hospital, were included. Survival data, comprising progression-free survival (PFS), overall survival (OS), time to intracranial progression (TTicP, with deaths censored) and brain PFS, were evaluated.
Results
During the study period, 79 (50.6%) patients underwent chemotherapy without atezolizumab, while 77 (49.4%) patients received AECb as their initial treatment. The median follow-up duration was 23.8 months, and there were no discernible differences between two groups in terms of age, sex and primary metastatic sites. Patients in the AECb group exhibited improved CNS outcomes: 27 (34.2%) and 16 (20.8%) patients experienced intracranial progression, with 24 (30.4%) and 14 (18.2%) cases of new brain metastasis. Both TTicP (median: 14.6 months vs. not reached; 12-month TTicP rate: 65.4% vs. 84.4%, P = 0.003) and brain PFS (median: 8.2 vs. 11.7 months; 12-month brain PFS rate 30.2% vs. 48.6%, P = 0.001) were significantly prolonged in the AECb group. These findings remained consistent even after adjusting for age, initial metastatic site, and prophylactic cranial irradiation (PCI). As expected, the AECb group demonstrated favorable survival outcomes, marked by improved PFS (median: 4.4 vs. 4.6 months, P = 0.004) and OS (median: 10.2 vs. 12.6 months, P = 0.001).
Conclusions
The addition of atezolizumab to conventional chemotherapy not only enhances patients’ survival but also improves intracranial disease control, thereby extending the duration of time to intra-cranial progression. This is first real-world data supporting benefits of atezolizumab in controlling intracranial progression in SCLC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
372P - Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy
Presenter: Manoj Gupta
Session: Poster Display
Resources:
Abstract
373P - Investigating the impact of treatment on geriatric patients with locally advanced head and neck squamous cell carcinoma
Presenter: Yen Ting Liu
Session: Poster Display
Resources:
Abstract
374P - Immunohistochemical evaluation of oral lichen planus: A prospective clinical study
Presenter: Saravanan Sampoornam Pape
Session: Poster Display
Resources:
Abstract
375P - Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital, Thailand
Presenter: wanit samadee
Session: Poster Display
Resources:
Abstract
376P - Nutrition as an independent prognostic factor in locally advanced nasopharyngeal carcinoma: A retrospective cohort study and propensity score-matched analysis
Presenter: haizhen yi
Session: Poster Display
Resources:
Abstract
377P - Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy
Presenter: Parth Verma
Session: Poster Display
Resources:
Abstract
378P - A real-world retrospective analysis of the efficacy of pembrolizumab combined with chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA HNSCC)
Presenter: zhu Liu
Session: Poster Display
Resources:
Abstract
379P - Nimotuzumab in combination with chemoradiation for patients with intermediate stage and locally advanced nasopharyngeal carcinoma: A retrospective comparative analysis using 5-year real-world survival data
Presenter: Andhika Rachman
Session: Poster Display
Resources:
Abstract
380P - An epidemiological analysis on the prevalence of oral cancer and its awareness among Irula tribes of South India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
381P - P16INK4 over-expression, early stages, keratinization, and surgical margin-free status are associated with better prognosis of oral squamous cell carcinoma (OSCC)
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract